Department of Psychiatry, University Hospital Louis-Mourier, Assistance Publique-Hôpitaux de Paris (AP-HP), 178 rue des Renouillers, Colombes, France.
Faculty of Medicine, University Paris 7 Denis Diderot, Paris, France.
Eur Arch Psychiatry Clin Neurosci. 2017 Oct;267(7):629-638. doi: 10.1007/s00406-017-0767-0. Epub 2017 Feb 11.
Cannabis use is associated with an increased risk of schizophrenia, and is considered to impact late neurodevelopment. Neurological soft signs (NSS) associated with schizophrenia are considered as markers of early neurodevelopmental impairment. Our study examines the association between heavy cannabis use before the onset of psychosis and clinical, neuropsychological and neurological symptoms, including NSS. In a cross-sectional study, we consecutively included 61 patients with schizophrenia (34 reporting heavy cannabis use before the onset of psychosis and 27 not reporting such use), in the setting of a University Hospital and a Medical Center. Symptoms assessment and substance use disorder were evaluated with the Diagnostic Interview for Genetic Studies. NSS were assessed with the Neurological Evaluation Scale. Psychopathology was assessed with the Positive and Negative Symptom Scale. All patients underwent a battery of neurocognitive tests evaluating attention, memory and executive functions domains. Patients with heavy cannabis use before the onset of psychosis showed significantly less NSS (p < 0.05), less negative symptoms (p < 10) and a better cognitive functioning in different domains [median reaction time (p = 0.03), episodic memory (p = 0.04), visuoconstructive praxs (p = 0.03) than their non-heavy user counterparts]. Confounding effects of alcohol and tobacco were taken into account. Age and gender were not statistically different between the two groups (p = 0.70 and p = 0.16, respectively). Our study supports the clinical, neuropsychological and neurological specificity associated with the heavy use of cannabis before the onset of schizophrenia. Patients with heavy cannabis use before the onset of schizophrenia may exhibit later neurodevelopmental impairment than those who do not report such use. Schizophrenia associated with heavy cannabis use could represent a specific phenotype.
大麻使用与精神分裂症风险增加有关,并被认为会影响晚期神经发育。与精神分裂症相关的神经软体征(NSS)被认为是早期神经发育障碍的标志物。我们的研究检查了精神病发作前重度大麻使用与临床、神经心理学和神经系统症状(包括 NSS)之间的关联。在一项横断面研究中,我们连续纳入了 61 名精神分裂症患者(34 名报告在精神病发作前重度大麻使用,27 名未报告此类使用),分别在一家大学医院和一家医疗中心进行。使用遗传研究诊断访谈评估症状评估和物质使用障碍。使用神经评估量表评估 NSS。使用阳性和阴性症状量表评估精神病症状。所有患者均接受了一系列神经认知测试,评估注意力、记忆和执行功能领域。与非重度使用者相比,精神病发作前重度使用大麻的患者 NSS 显著减少(p<0.05),阴性症状更少(p<10),不同领域的认知功能更好[中位数反应时间(p=0.03),情景记忆(p=0.04),视空间构建(p=0.03)]。考虑到酒精和烟草的混杂影响。两组间年龄和性别无统计学差异(p=0.70 和 p=0.16)。我们的研究支持与精神分裂症发病前重度大麻使用相关的临床、神经心理学和神经学特异性。与未报告此类使用的患者相比,发病前重度使用大麻的精神分裂症患者可能表现出更晚的神经发育障碍。与重度大麻使用相关的精神分裂症可能代表一种特定的表型。